{"id":757,"date":"2018-09-09T12:00:41","date_gmt":"2018-09-09T10:00:41","guid":{"rendered":"http:\/\/ibtherapeutics.com\/?page_id=757"},"modified":"2025-10-06T15:15:55","modified_gmt":"2025-10-06T13:15:55","slug":"shares","status":"publish","type":"page","link":"https:\/\/ibtherapeutics.com\/sv\/investerare\/shares\/","title":{"rendered":"Aktien"},"content":{"rendered":"<p>Infant Bacterial Therapeutics ABs serie B-aktier \u00e4r noterad p\u00e5 Nasdaq Stockholm sedan\u00a0den 10 september 2018.<\/p>\n<p>Antalet aktier i Infant Bacterial Therapeutics AB uppg\u00e5r till 453 283 A-aktier med 10 r\u00f6str\u00e4tter per aktier och 13 018 137 B-aktier med en r\u00f6str\u00e4tt per aktie, totalt 13 471 420 aktier.<\/p>\n<h2>Analytiker<\/h2>\n<p>Analytiker som f\u00f6ljer IBT<\/p>\n<p>SEB: Christopher W. Uhde, PhD och Mattias Vadsten.<\/p>\n<h2>Handelsinformation<\/h2>\n<p>Kortnamn p\u00e5 Nasdaq Stockholm: IBT B<\/p>\n<p>ISIN-kod B-aktie: SE0008015259<\/p>\n<p>Aktierna \u00e4r registrerade av Euroclear Sweden AB. Klicka\u00a0<a href=\"http:\/\/www.nasdaqomxnordic.com\/aktier\/microsite?Instrument=SSE120381&amp;name=Infant%20Bacterial%20TherapeuticsB\">h\u00e4r<\/a>\u00a0f\u00f6r aktuell aktieinformation fr\u00e5n Nasdaq OMX Stockholm.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Infant Bacterial Therapeutics ABs serie B-aktier \u00e4r noterad p\u00e5 Nasdaq Stockholm sedan\u00a0den 10 september 2018. Antalet aktier i Infant Bacterial Therapeutics AB uppg\u00e5r till 453 283 A-aktier med 10 r\u00f6str\u00e4tter per aktier och 13 018 137 B-aktier med en r\u00f6str\u00e4tt per aktie, totalt 13 471 420 aktier. Analytiker Analytiker som f\u00f6ljer IBT SEB: Christopher W. [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":0,"parent":622,"menu_order":31,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages\/757"}],"collection":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=757"}],"version-history":[{"count":41,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages\/757\/revisions"}],"predecessor-version":[{"id":4309,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages\/757\/revisions\/4309"}],"up":[{"embeddable":true,"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/pages\/622"}],"wp:attachment":[{"href":"https:\/\/ibtherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}